NewsBenzingaProtalix BioTherapeutics bekräftigt den Umsatz-Ausblick für das Geschäftsjahr 2026 von 78,000 Mio. $ bis 83,000 Mio. $ gegenüber der Schätzung von 71,359 Mio. $ Protalix BioTherapeutics bekräftigt den Umsatz-Ausblick für das Geschäftsjahr 2026 von 78,000 Mio. $ bis 83,000 Mio. $ gegenüber der Schätzung von 71,359 Mio. $ Benzinga 2026.11.10 11:48 (GMT+0) Open on Benzinga Other news CalPERS Discloses $37.1 Million Stake in Strategy Scammers Used Musk Deepfake Video to Defraud; Coinbase AI System Blocked $4.7 Million JPMorgan Is Developing AI Agent Trading Without Human Involvement Coinbase CEO: AI Agents to Account for Well Over 99.9% of Trading Volume Within a Decade; Bitcoin May Have Bottomed This Cycle Jito CEO: Crypto Developers Should Slow Down in the Next Two Years and Focus on Fixing Security Flaws Glassnode: Bitcoin Sell-Off Nears Historical Local Bottom Levels, $62,000 Becomes Key Line of Defense
Coinbase CEO: AI Agents to Account for Well Over 99.9% of Trading Volume Within a Decade; Bitcoin May Have Bottomed This Cycle
Jito CEO: Crypto Developers Should Slow Down in the Next Two Years and Focus on Fixing Security Flaws
Glassnode: Bitcoin Sell-Off Nears Historical Local Bottom Levels, $62,000 Becomes Key Line of Defense